American College of Toxicology 31st Annual Meeting

Corporate consolidation, restructuring and changing business models have had a major impact on how pre-clinical development is managed. Traditional internal resources such as drug discovery and safety assessment laboratories are now being reduced or replaced with partnerships, in-licensed molecules and out-sourced services. ................
................

In order to avoid copyright disputes, this page is only a partial summary.